Factors Affecting Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasis

Basit Öğe Kaydı
dc.authoridharputluoglu, hakan/0000-0001-8537-5941
dc.authorwosidharputluoglu, hakan/ABI-6451-2020
dc.contributor.authorHarputluoglu, Hakan
dc.contributor.authorKaplan, Nihal
dc.contributor.authorDikilitas, Mustafa
dc.contributor.authorYagar, Yavuz
dc.date.accessioned2024-08-04T20:42:53Z
dc.date.available2024-08-04T20:42:53Z
dc.date.issued2016
dc.departmentİnönü Üniversitesien_US
dc.description.abstractIn this study, prognostic factors in non small cell lung cancer (NSCLC) patients with brain metastasis, and relation between brain metastasis location and survival were investigated. 103 NSCLC patients with brain metastasis were enrolled in this study. Demographic, clinical characteristics and treatment modalities of the patients who were followed up in medical oncology department between May 2009 and February 2015 were assessed retrospectively using the hospital database. Brain metastasis location, treatment of brain metastasis, systemic treatment after brain metastasis and survival of the patients were recorded. The relation between these factors and survival was assessed. Follow-up period of the patients was between one and 42 months. Mean survival of the patients after brain metastasis diagnosis was 7.2 months. In the single variant analyses; patient age below 65, good performance status, detection of brain metastasis during initial diagnosis and receiving systemic treatment after brain metastasis were found to be positive prognostic factors. In the multivariant analyses; while combined treatment of brain metastasis with surgery and radiotherapy and systemic therapy after brain metastasis were found to be independent prognostic factors, no relation between location of brain metastasis and survival was found. In this study, systemic therapy including surgery, radiotherapy and chemotherapy was found as independent prognostic factors in selected patients who had NSCLC with brain metastasis. We think that defining prognostic factors in lung cancer patients with brain metastasis is important for both estimating prognosis and selecting optimal therapy for the patient.en_US
dc.identifier.doi10.4999/uhod.161687
dc.identifier.endpage205en_US
dc.identifier.issn1306-133X
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85008433270en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage199en_US
dc.identifier.urihttps://doi.org/10.4999/uhod.161687
dc.identifier.urihttps://hdl.handle.net/11616/97655
dc.identifier.volume26en_US
dc.identifier.wosWOS:000392460400002en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherAkad Doktorlar Yayinevien_US
dc.relation.ispartofUhod-Uluslararasi Hematoloji-Onkoloji Dergisien_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectLung canceren_US
dc.subjectBrain metastasisen_US
dc.subjectSurvivalen_US
dc.titleFactors Affecting Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu